Company Monitoring Page for Sunovion

job ratings for Sunovion

09/26/18
industry:
Big Pharma
company:
Sunovion
job rating:
5
The people I work with
08/28/18
industry:
Bio-pharmaceutical
company:
Sunovion
job rating:
4
Back to the old selling model. Little tweaks BS. Let me sell and work. Too many co rides. It’s a hindrance. Office ask why my manager is with me so much?

latest headlines for company on cafepharma

Sunovion, Otsuka randomize first patient for GAD Phase II/III study
Clinical Trials Arena
Thu, 04/27/23 - 10:27 am
Tags:
Sunovion, Otsuka, clinicat trials, ulotaront, generalized anxiety disorder
Schizophrenia: Four major clinical trials to watch in 2023
Clinical Trials Arena
Thu, 04/13/23 - 10:08 pm
Tags:
clinical trials, schizophrenia, Reviva, brilaroxazine, Newron, evenamide, Sunovion, ulotaront, Acadia Pharma, pimavanserin
Sunovion pens $890M Otsuka pact for a clutch of neuropsychiatric drugs
Fierce Biotech
Thu, 09/30/21 - 10:52 am
Tags:
Sunovion, Otsuka, biobucks, neuropsychiatric
Drugs facing the most patent expirations this year
Drug Patent Watch
Sun, 08/1/21 - 11:46 pm
Tags:
patents, Novartis, Sunovion, Allergan, Bayer, Gilead Sciences
Sunovion takes Urovant's overactive bladder med Gemtesa to primary care docs as promo partnership launches
Fierce Pharma
Tue, 07/13/21 - 10:59 am
Tags:
Urovant Sciences, Gemtesa, Sunovion, overactive bladder
Sunovion’s SEP-4199 fails to meet primary endpoint in SEP380-201 trial
Pharmaceutical Business Review
Tue, 07/7/20 - 10:45 am
Tags:
Sunovion, clinical trials, SEP-4199, bipolar disorder
Sunovion Drug Gets FDA Nod for Treating Parkinson’s “Off” Episodes
Xconomy
Thu, 05/21/20 - 11:14 pm
Tags:
Sunovion, FDA, Parkinson's Disease, Kynmobi
Sunovion announces acceptance by FDA of NDA for Dasotraline to treat Binge Eating Disorder
Pharmaceutical Business Review
Wed, 07/31/19 - 11:59 pm
Tags:
Sunovion, FDA, dasotraline, binge eating disorder
Sunovion’s SEP-363856 gets FDA breakthrough status for schizophrenia
Pharmaceutical Business Review
Tue, 05/14/19 - 09:24 am
Tags:
Sunovion, PsychoGenics, breakthrough therapies, SEP-363856, schizophrenia
Sunovion Pharma Promotes Antony Loebel to President & CEO
Xconomy
Wed, 03/6/19 - 08:21 pm
Tags:
Sunovion, Antony Loebel
Sunovion Receives Complete Response Letter from FDA for Parkinson’s Disease Drug
CP Wire
Thu, 01/31/19 - 10:23 am
Tags:
Sunovion, Parkinson's Disease, apomorphine sublingual film, APL-130277, FDA, complete response letter
Thu, 01/31/19 - 10:19 am
Tags:
Sunovion, Parkinson's Disease, apomorphine sublingual film, APL-130277
2018 in review: How patient centricity led to new drugs that tackle unmet need
Pharmaforum
Mon, 12/17/18 - 09:22 am
Tags:
patients, drug development, Sunovion, Sangamo, Amryt Pharma
Sunovion Receives Bad News From the FDA About ADHD Drug
CP Wire
Fri, 08/31/18 - 10:45 am
Tags:
Sunovion, CRL, NDA, dasotraline, ADHD, FDA, complete response letter
Fri, 08/31/18 - 10:42 am
Tags:
Sunovion, complete response letter, dasotraline, ADHD
Sunovion drug cuts binge eating days at higher dose
Biopharma Dive
Thu, 07/26/18 - 11:49 am
Tags:
Sunovion, dasotraline, binge eating
FDA to review Sunovion’s apomorphine sublingual film for Parkinson’s disease
Drug Delivery Business News
Wed, 06/13/18 - 10:21 pm
Tags:
Sunovion, FDA, Parkinson's Disease, Apomorphine
Sunovion touts pivotal Ph3 trial for Parkinson’s drug
Drug Delivery Business News
Tue, 01/30/18 - 10:45 pm
Tags:
Sunovion, clinical trials, Parkinson's Disease, Apomorphine
Sunovion divests asthma, allergy tech to Covis Pharma
Drug Delivery Business News
Thu, 07/13/17 - 09:23 pm
Tags:
Sunovion, asthma, Covis Pharma, Alvesco, Omnaris
Sunovion seeks FDA nod for COPD treatment – again
Drug Delivery Business News
Fri, 06/30/17 - 10:47 am
Tags:
Sunovion, FDA, COPD, eFlow, drug-device combos, devices

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.